Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy

• Published in: Clinical cancer research 2005-10, Vol.11 (19), p.7146s-7150s
• Main Authors: JACOBS, Samuel A, VIDNOVIC, Nicholas, JOYCE, Judith, MCCOOK, Barry, TOROK, Frank, AVRIL, Norbert
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Aged; Antibodies, Monoclonal - therapeutic use; Antigens, CD20 - biosynthesis; Antineoplastic agents; Biological and medical sciences; Blood Platelets - metabolism; Clinical Trials as Topic; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Female; Fluorodeoxyglucose F18; Humans; L-Lactate Dehydrogenase - metabolism; Lymphoma, Non-Hodgkin - therapy; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Platelet Count; Pleural Effusion - pathology; Positron-Emission Tomography; post-ABMT therapy; Radioimmunotherapy - methods; Recurrence; relapsed non–Hodgkin's lymphoma; Time Factors; Tomography, X-Ray Computed - methods; Treatment Outcome; Yttrium Radioisotopes - therapeutic use; zevalin
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-1004-0003

Purpose : Targeted radioimmunotherapy with yttrium-90 ( 90 Y)–labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non–Hodgkin's lymphoma. Eligibility criteria used in phase I trials, and adopted in phase II and III trials, excluded patients with prior myeloablative therapy. We treated eight patients with 90 Y ibritumomab tiuxetan who had prior autologous stem cell transplant, but met all other treatment criteria. Experimental Design: Eight patients with CD20+ non–Hodgkin's lymphoma had extensive prior therapy including myeloablative chemotherapy but did not receive total body irradiation. Each had bone marrow cellularity of >15%, platelet count of >100,000/mm 3 , and one had documented lymphomatous bone marrow involvement of